The plan is to transfuse COVID-19 infected patients with convalescent plasma and observe whether this will result in a significant improvement in clinical outcome in comparison to historical experience.
Biological: Convalescent Plasma
200-425mL convalescent plasma donated by patients previously positive for COVID-19
Inclusion Criteria:
- Documented COVID-19 infection by nasal pharyngeal sampling
- COVID-19 disease falling into one of the following groups:
- Critical disease: respiratory failure requiring mechanical ventilation, pressor
support, or multiple organ dysfunction/failure
- Severe disease: tachypnea >/=30 per min, O2 sats
- High Risk: upper respiratory symptoms but no radiographic evidence of disease,
immunocompromised, insulin-dependent diabetes, poorly controlled HIV disease, moderate
to severe asthma history, severe COPD, morbid obesity (BMI >/=40, age >/=65 years
- Health Care Providers: health care providers at risk to exposure to COVID-19 infection
or those with mild to non-severe disease
Exclusion Criteria:
- History of IgA deficiency
- History of anaphylatic reaction to blood product transfusion including
hypersensitivity to immunoglobulin therapy
Northside Hospital
Atlanta, Georgia, United States
Kent Holland, MD, Principal Investigator
Northside Hospital